Skip to main content
Erschienen in: Archives of Dermatological Research 2/2016

01.03.2016 | Concise Communication

The high incidence of anti-Ro/SSA and anti-p200 antibodies in female patients with connective tissue diseases confirms the importance of screening for congenital heart block-associated autoantibodies during pregnancy

verfasst von: E. Cozzani, Arianna Fay Agnoletti, F. Pappalardo, I. Schiavetti, A. Torino, A. Parodi

Erschienen in: Archives of Dermatological Research | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

It is known that anti-Ro/SSA positivity leads to higher risk of miscarriage and fetal cardiac malformations. Particularly, anti-p200 antibodies against a finer specificity of the Ro/SSA antigen, have been associated with congenital heart block. The aim of the study was to assess the frequency of anti-p200 among female patients with different connective tissue diseases and, among these, the relevance of anti-p200 values in patients with cutaneous diseases compared to systemic diseases. Anti-p200 were investigated in 110 anti-Ro/SSA positive female sera, sent to our laboratory between 2008 and 2014 with suspect of connective disease, by using ELISA testing. Positivity was found in 40.9 % samples, 34 of them showed a strong positivity (values ≥ 1.0, cut off = 0.7). Patients with systemic diseases were anti-p200 positive in the 45.9 % of cases while patients with cutaneous diseases were positive in the 24.0 % of cases. Positivity for anti-p200 antibodies was revealed in 24.0 % of patients with discoid lupus erythematosus; 100 % of patients with dermatomyositis; 40.0 % of patients with mixed connective tissue disease; 25.0 % of patients with rheumatoid arthritis; 100 % of patients with Sjögren’s syndrome; 33.3 % of patients with subacute cutaneous lupus erythematosus; 42.9 % of patients with systemic lupus erythematosus; 80.0 % of patients with systemic sclerosis. No significant difference in anti-p200 prevalence was found between systemic and cutaneous involvement, nevertheless, considering only positive sera, the antibody titer was higher in systemic diseases rather than in cutaneous diseases (2.6 ± 1.7 and 1.7 ± 1.9; p = 0.041). The authors think screenings for anti-Ro/SSA and anti-p200 antibodies should be included in the laboratory checklist for pregnancy.
Literatur
1.
Zurück zum Zitat Boutjdir M (2000) Molecular and ionic basis of congenital complete heart block. Trends Cardiovasc Med 10:114–122CrossRefPubMed Boutjdir M (2000) Molecular and ionic basis of congenital complete heart block. Trends Cardiovasc Med 10:114–122CrossRefPubMed
2.
Zurück zum Zitat Brucato A (2008) Prevention of congenital heart block in children of SSA-positive mothers. Rheumatology 47:35–37CrossRef Brucato A (2008) Prevention of congenital heart block in children of SSA-positive mothers. Rheumatology 47:35–37CrossRef
3.
Zurück zum Zitat Brucato A, Doria A, Frassi M, Castellino G, Franceschini F, Faden D, Pisoni MP, Solerte L, Muscarà M, Lojacono A, Motta M, Cavazzana I, Ghirardello A, Vescovi F, Tombini V, Cimaz R, Gambari PF, Meroni PL, Canesi B, Tincani A (2002) Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. Lupus 11:716–721CrossRefPubMed Brucato A, Doria A, Frassi M, Castellino G, Franceschini F, Faden D, Pisoni MP, Solerte L, Muscarà M, Lojacono A, Motta M, Cavazzana I, Ghirardello A, Vescovi F, Tombini V, Cimaz R, Gambari PF, Meroni PL, Canesi B, Tincani A (2002) Pregnancy outcome in 100 women with autoimmune diseases and anti-Ro/SSA antibodies: a prospective controlled study. Lupus 11:716–721CrossRefPubMed
4.
Zurück zum Zitat Carazzai AM, Sucena RC, Milano SI, Munhoz EG, Santos RA, Scheinberg MA (1988) Detection of SSA/Ro antibody in patients with systemic lupus erythematosus, discoid lupus erythematosus and cutaneous photosensitivity. A comparative study. Rev Paul Med 106:71–74PubMed Carazzai AM, Sucena RC, Milano SI, Munhoz EG, Santos RA, Scheinberg MA (1988) Detection of SSA/Ro antibody in patients with systemic lupus erythematosus, discoid lupus erythematosus and cutaneous photosensitivity. A comparative study. Rev Paul Med 106:71–74PubMed
5.
Zurück zum Zitat Clancy RM, Buyon JP, Ikeda K, Nozawa K, Argyle DA, Friedman DM, Chan EK (2005) Maternal antibody responses to the 52-kd SSA/RO p200 peptide and the development of fetal conduction defects. Arthritis Rheum 52:3079–3086CrossRefPubMed Clancy RM, Buyon JP, Ikeda K, Nozawa K, Argyle DA, Friedman DM, Chan EK (2005) Maternal antibody responses to the 52-kd SSA/RO p200 peptide and the development of fetal conduction defects. Arthritis Rheum 52:3079–3086CrossRefPubMed
6.
Zurück zum Zitat Costedoat-Chalumeau N, Amoura Z, Villain E, Cohen L, Piette JC (2005) Anti-SSA/Ro antibodies and the heart: more than complete congenital heart block? A review of electrocardiographic and myocardial abnormalities and of treatment options. Arthritis Res Ther 7:69–73PubMedCentralCrossRefPubMed Costedoat-Chalumeau N, Amoura Z, Villain E, Cohen L, Piette JC (2005) Anti-SSA/Ro antibodies and the heart: more than complete congenital heart block? A review of electrocardiographic and myocardial abnormalities and of treatment options. Arthritis Res Ther 7:69–73PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Lazzerini PE, Capecchi PL, Laghi-Pasini F (2010) Anti-Ro/SSA antibodies and cardiac arrhythmias in the adult: facts and hypotheses. Scand J Immunol 72:213–222CrossRefPubMed Lazzerini PE, Capecchi PL, Laghi-Pasini F (2010) Anti-Ro/SSA antibodies and cardiac arrhythmias in the adult: facts and hypotheses. Scand J Immunol 72:213–222CrossRefPubMed
8.
Zurück zum Zitat Strandberg L, Winqvist O, Sonesson SE, Mohseni S, Salomonsson S, Bremme K, Buyon JP, Julkunen H, Wahren-Herlenius M (2008) Antibodies to amino acid 200–239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block. Clin Exp Immunol 154:30–37PubMedCentralCrossRefPubMed Strandberg L, Winqvist O, Sonesson SE, Mohseni S, Salomonsson S, Bremme K, Buyon JP, Julkunen H, Wahren-Herlenius M (2008) Antibodies to amino acid 200–239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block. Clin Exp Immunol 154:30–37PubMedCentralCrossRefPubMed
Metadaten
Titel
The high incidence of anti-Ro/SSA and anti-p200 antibodies in female patients with connective tissue diseases confirms the importance of screening for congenital heart block-associated autoantibodies during pregnancy
verfasst von
E. Cozzani
Arianna Fay Agnoletti
F. Pappalardo
I. Schiavetti
A. Torino
A. Parodi
Publikationsdatum
01.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Dermatological Research / Ausgabe 2/2016
Print ISSN: 0340-3696
Elektronische ISSN: 1432-069X
DOI
https://doi.org/10.1007/s00403-016-1622-2

Weitere Artikel der Ausgabe 2/2016

Archives of Dermatological Research 2/2016 Zur Ausgabe

Leitlinien kompakt für die Dermatologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Studienlage spricht für Isotretinoin zur Rosazea-Therapie

23.05.2024 Rosazea Nachrichten

Isotretinoin wird off-label zur Behandlung von Rosazea eingesetzt. Wie solide die Evidenz dafür ist, wurde jetzt in einem systematischen Review überprüft.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Riesenzellarteriitis: 15% der Patienten sind von okkulter Form betroffen

16.05.2024 Riesenzellarteriitis Nachrichten

In einer retrospektiven Untersuchung haben Forschende aus Belgien und den Niederlanden die okkulte Form der Riesenzellarteriitis genauer unter die Lupe genommen. In puncto Therapie und Rezidivraten stellten sie keinen sehr großen Unterschied zu Erkrankten mit kranialen Symptomen fest.

Update Dermatologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.